BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 22682027)

  • 21. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Garderet L; Iacobelli S; Moreau P; Dib M; Lafon I; Niederwieser D; Masszi T; Fontan J; Michallet M; Gratwohl A; Milone G; Doyen C; Pegourie B; Hajek R; Casassus P; Kolb B; Chaleteix C; Hertenstein B; Onida F; Ludwig H; Ketterer N; Koenecke C; van Os M; Mohty M; Cakana A; Gorin NC; de Witte T; Harousseau JL; Morris C; Gahrton G
    J Clin Oncol; 2012 Jul; 30(20):2475-82. PubMed ID: 22585692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
    Gay F; Magarotto V; Crippa C; Pescosta N; Guglielmelli T; Cavallo F; Pezzatti S; Ferrari S; Liberati AM; Oliva S; Patriarca F; Offidani M; Omedé P; Montefusco V; Petrucci MT; Giuliani N; Passera R; Pietrantuono G; Boccadoro M; Corradini P; Palumbo A
    Blood; 2013 Aug; 122(8):1376-83. PubMed ID: 23775712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].
    Li J; Liu JR; Huang BH; Chen M; Zheng D; Xu DR; Zou WY
    Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):279-83. PubMed ID: 22781947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
    Dunavin NC; Wei L; Elder P; Phillips GS; Benson DM; Hofmeister CC; Penza S; Greenfield C; Rose KS; Rieser G; Merritt L; Ketcham J; Heerema N; Byrd JC; Devine SM; Efebera YA
    Leuk Lymphoma; 2013 Aug; 54(8):1658-64. PubMed ID: 23194056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
    Landau H; Pandit-Taskar N; Hassoun H; Cohen A; Lesokhin A; Lendvai N; Drullinsky P; Schulman P; Jhanwar S; Hoover E; Bello C; Riedel E; Nimer SD; Comenzo RL
    Leuk Lymphoma; 2012 Feb; 53(2):275-81. PubMed ID: 21824051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
    Terpos E; Christoulas D; Kastritis E; Roussou M; Migkou M; Eleutherakis-Papaiakovou E; Gavriatopoulou M; Gkotzamanidou M; Kanellias N; Manios E; Papadimitriou C; Dimopoulos MA
    Leukemia; 2014 Apr; 28(4):928-34. PubMed ID: 24045498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients.
    Buda G; Orciuolo E; Carulli G; Galimberti S; Ghio F; Cervetti G; Pelosini M; Petrini M
    Acta Haematol; 2013; 129(1):35-9. PubMed ID: 23107867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients.
    Chen RA; Tu Y; Cao Y; Liu L; Liang Y
    J Int Med Res; 2011; 39(5):1975-84. PubMed ID: 22118002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study.
    Huang BT; Tan Y; Zhao WH; Zeng QC; Li BS; Chen RL
    J Cancer Res Clin Oncol; 2014 Feb; 140(2):303-9. PubMed ID: 24337419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of high-dose melphalan with autologous stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy.
    Lee BH; Shin SH; Min CK; Yhim HY; Kwak JY; Kim JA
    Int J Hematol; 2013 May; 97(5):634-9. PubMed ID: 23605366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modified bortezomib, adriamycin and dexamethasone (PAD) regimen in advanced multiple myeloma.
    Zhang Y; Liu H; Chen X; Bai Q; Liang R; Shi B; Liu L; Tian D; Liu M
    Pathol Oncol Res; 2014 Oct; 20(4):987-95. PubMed ID: 24942506
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.
    Mai EK; Bertsch U; Dürig J; Kunz C; Haenel M; Blau IW; Munder M; Jauch A; Schurich B; Hielscher T; Merz M; Huegle-Doerr B; Seckinger A; Hose D; Hillengass J; Raab MS; Neben K; Lindemann HW; Zeis M; Gerecke C; Schmidt-Wolf IG; Weisel K; Scheid C; Salwender H; Goldschmidt H
    Leukemia; 2015 Aug; 29(8):1721-9. PubMed ID: 25787915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis.
    Sekine L; Ziegelmann PK; Manica D; da Fonte Pithan C; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
    Hematol Oncol; 2019 Feb; 37(1):62-74. PubMed ID: 30129104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
    Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
    Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
    Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
    Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy.
    van Rhee F; Szymonifka J; Anaissie E; Nair B; Waheed S; Alsayed Y; Petty N; Shaughnessy JD; Hoering A; Crowley J; Barlogie B
    Blood; 2010 Aug; 116(8):1220-7. PubMed ID: 20501894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.